ArticleRSC advances2020
Rapid isolation of antigen-specific B-cells using droplet microfluidics.
Article in RSC advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 46 citations in OpenAlex.
- Streamlined stable CHO cell line development using droplet microfluidics with image-based monoclonality assessment.Bioprocess and biosystems engineering · 2026Article
- Article
- Rapid discovery of monoclonal antibodies by microfluidics-enabled FACS of single pathogen-specific antibody-secreting cells.Nature biotechnology · 2025Article
- Fluorescence-activated droplet sequencing (FAD-seq) directly provides sequences of screening hits in antibody discovery.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- A Microfluidic Strategy to Capture Antigen-Specific High-Affinity B Cells.Advanced nanobiomed research · 2024Article
- Antibodies, repertoires and microdevices in antibody discovery and characterization.Lab on a chip · 2024Review
- Deep learning enabled label-free microfluidic droplet classification for single cell functional assays.Frontiers in bioengineering and biotechnology · 2024Article
- Advancements in mammalian display technology for therapeutic antibody development and beyond: current landscape, challenges, and future prospects.Frontiers in immunology · 2024Review
- A rapid cell-free expression and screening platform for antibody discovery.Nature communications · 2023Article
- Characterization of a Riboflavin-Producing Mutant ofMicroorganisms · 2023Article
- A high throughput bispecific antibody discovery pipeline.Communications biology · 2023Article
- Cell-Free Production Systems in Droplet Microfluidics.Advances in biochemical engineering/biotechnology · 2023Review
- High-throughput single-cell antibody secretion quantification and enrichment using droplet microfluidics-based FRET assay.iScience · 2022Article
- Review
- Acoustofluidic Droplet Sorter Based on Single Phase Focused Transducers.Small (Weinheim an der Bergstrasse, Germany) · 2021Article
- Single-Cell Technologies for the Study of Antibody-Secreting Cells.Frontiers in immunology · 2021Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Monoclonal antibodies are powerful tools for scientific research and are the basis of numerous therapeutics. However, traditional approaches to generate monoclonal antibodies against a desired target, such as hybridoma-based techniques and display library methods, are laborious and suffer from fusion inefficiency and display bias, respectively. Here we present a platform, featuring droplet microfluidics and a bead-based binding assay, to rapidly identify and verify antigen-binding antibody sequences from primary cells. We used a defined mixture of hybridoma cells to characterize the system, sorting droplets at up to 100 Hz and isolating desired hybridoma cells, comprising 0.1% of the input, with a false positive rate of less than 1%. We then applied the system to once-frozen primary B-cells to isolate rare cells secreting target-binding antibody. We performed RT-PCR on individual sorted cells to recover the correctly paired heavy- and light-chain antibody sequences, and we used rapid cell-free protein synthesis to generate single-chain variable fragment-format (scFv) antibodies from fourteen of the sorted cells. Twelve of these showed antigen-specific binding by ELISA. Our platform facilitates screening animal B-cell repertoires within days at low cost, increasing both rate and range of discovering antigen-specific antibodies from living organisms. Further, these techniques can be adapted to isolate cells based on virtually any secreted product.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.